Humana Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Humana Inc trades at $445 (market cap $47.61B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.71 (market cap $3.16B). The key difference: Humana Inc is far larger — about 15.1× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Humana Inc pays a 0.89% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| HUM | SPHD | |
|---|---|---|
Market Cap | $47.61B | $3.16B |
Volume | 1,827,332 | 1,245,780 |
Sector | Health | — |
52-Week High | $409.85 | $53.55 |
52-Week Low | $163.67 | $46.96 |
Typical Hold Time | 53 Days | 125 Days |
Enterprise Value | $54.97B | — |
Dividend Yield | 0.89% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $387.12, down 4.24% today, but maintains a bullish technical outlook with strong institutional support. The stock shows mixed fundamentals with revenue growth to $129.66B in 2025 but declining profit margins at 0.88%. Recent analyst upgrades, including Barclays' $515 target on September 25, 2026, highlight optimism despite ongoing Medicare Advantage plan adjustments affecting member transitions.
Investment outlook remains cautiously optimistic with a consensus price target of $432.63 offering 12% upside. Risks include margin compression, regulatory scrutiny from Medicare billing practices, and competitive pressures in managed care. The company's strong cash position of $20.44B and consistent dividend payments provide stability amid enrollment volatility.
SPHD trades at $48.19, down 0.58% with a bearish technical outlook showing 17 sell signals versus 4 buy signals. The ETF maintains its high-dividend focus with recent payouts of $0.20-$0.21, though financial ratios remain unavailable. Technical indicators show oversold conditions with RSI at 6.33-14.37 levels while moving averages signal continued downward pressure.
The ETF faces headwinds from underperformance concerns versus peers like SCHD, with media highlighting decade-long return disparities. While monthly dividends appeal to income investors, the lack of quality screening in stock selection poses yield trap risks. Current sentiment leans cautious as analysts question the fund's total return potential amid market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →